New Trump Administration, New Republican Congress - Webinar CD/Transcript
New Trump Administration, New Republican Congress: What Will the FDA’s Agenda Be in 2017?
The US has a new president, a new Congress, and almost assuredly a new agenda for the FDA — with different policies and priorities than the current administration.
What does this mean for FDA regulated industries?
Steve Grossmann — a long-time D.C. insider, who served as a Senate Health Committee Staff Director and Deputy Assistant Secretary of Health — will discuss what the FDA is doing today and what it likely will be doing under the next administration.
After attending this session you will learn:
- The likelihood that the current commissioner will continue to head the agency —for how long — and who the top candidates are to replace him
- Who will head the FDA transition team and how the process will likely unfold in the next months
- What the FDA’s likely priorities will be in 2017 under the new administration besides the medical device tax and drug pricing and the signals you need to watch for to determine how the new policies will likely impact your company — and your job on a daily basis
- How the new Congress is likely to impact what FDA does in 2017 and whether there will be increased monitoring of specific FDA projects, offices and policies
Order today for a glimpse of what 2017 will bring for the FDA and its regulated industries.